Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
about
Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsEffects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells.Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
P2860
Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Activating transcription facto ...... eoblastogenesis by bortezomib.
@en
Activating transcription facto ...... eoblastogenesis by bortezomib.
@nl
type
label
Activating transcription facto ...... eoblastogenesis by bortezomib.
@en
Activating transcription facto ...... eoblastogenesis by bortezomib.
@nl
prefLabel
Activating transcription facto ...... eoblastogenesis by bortezomib.
@en
Activating transcription facto ...... eoblastogenesis by bortezomib.
@nl
P2093
P2860
P1476
Activating transcription facto ...... eoblastogenesis by bortezomib.
@en
P2093
Ayako Nakano
Hiroe Amou
Hirokazu Miki
Keiichiro Watanabe
Kumiko Kagawa
Kyoko Takeuchi
Masahiro Abe
Masahiro Hiasa
Shingen Nakamura
P2860
P2888
P356
10.1007/S12185-013-1367-Z
P577
2013-05-25T00:00:00Z